Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016
Published Jul 20, 2016
75 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects
- The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising

  
Source:
Document ID
GMDHC8256IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Opioid-Induced Constipation (OIC) Overview71
Therapeutics Development82
  Pipeline Products for Opioid-Induced Constipation (OIC) Overview81
  Pipeline Products for Opioid-Induced Constipation (OIC) Comparative Analysis91
Opioid-Induced Constipation (OIC) Therapeutics under Development by Companies101
Opioid-Induced Constipation (OIC) Therapeutics under Investigation by Universities/Institutes111
Opioid-Induced Constipation (OIC) Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Opioid-Induced Constipation (OIC) Products under Development by Companies151
Opioid-Induced Constipation (OIC) Products under Investigation by Universities/Institutes161
Opioid-Induced Constipation (OIC) Companies Involved in Therapeutics Development177
  Develco Pharma Schweiz AG171
  Ironwood Pharmaceuticals, Inc.181
  Shionogi &Co., Ltd.191
  Sucampo Pharmaceuticals, Inc.201
  Synergy Pharmaceuticals, Inc.211
  Theravance Biopharma, Inc.221
  Valeant Pharmaceuticals International, Inc.231
Opioid-Induced Constipation (OIC) Therapeutics Assessment2410
  Assessment by Monotherapy Products241
  Assessment by Combination Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration302
  Assessment by Molecule Type322
Drug Profiles3430
  (axelopran sulfate + oxycodone hydrochloride) Drug Profile341
  axelopran sulfate Drug Profile352
  dolcanatide Drug Profile373
  linaclotide Drug Profile407
  lubiprostone Drug Profile478
  methylnaltrexone bromide Drug Profile554
  methylnaltrexone bromide Drug Profile591
  naldemedine tosylate Drug Profile602
  naloxone hydrochloride PR Drug Profile621
  Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC Drug Profile631
Opioid-Induced Constipation (OIC) Dormant Projects641
Opioid-Induced Constipation (OIC) Discontinued Products651
Opioid-Induced Constipation (OIC) Product Development Milestones668
  Featured News &Press Releases661
    Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation661
    May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation661
    Apr 04, 2016: Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR671
    Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation671
    Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation671
    Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation681
    Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015691
    Sep 08, 2015: Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR701
    Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation701
    Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients711
    Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation711
    May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation711
    May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week721
    Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain721
    Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation731
Appendix742
  Methodology741
  Coverage741
  Secondary Research741
  Primary Research741
  Expert Panel Validation741
  Contact Us741
  Disclaimer751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Opioid-Induced-Constipation-OIC-Pipeline-Review-H2-2016-2088-16230>
  
APA:
Global Markets Direct - Market Research. (2016). Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Opioid-Induced-Constipation-OIC-Pipeline-Review-H2-2016-2088-16230>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.